New Delhi: Biotechnology major Biocon reported a 47 percent rise in its consolidated net profit to Rs 120 crore for the quarter ended June 2018 on account of robust performance across segments.
The company had posted a net profit of Rs 81 crore for the corresponding period of the previous fiscal, Biocon said in a filing to BSE.
Consolidated total revenue of the company stood at Rs 1,193 crore for the quarter under consideration. It was Rs 988 crore for the same period a year ago.
“We started the year with a robust Q1FY19 recording an overall revenue growth of 21 percent at Rs 1,193 crore and a 47 percent increase in net profit at Rs 120 crore, driven by a strong performance across our business segments,” Biocon Chairperson and MD Kiran Mazumdar-Shaw said.
This performance was led by a 36 percent growth in biologics business and a 39 percent increase in research services revenues, she added.
“The approval and launch of our biosimilar Pegfilgrastim, Fulphila, in the US is a significant milestone for Biocon and sets the tone for the future success of our biosimilars business,” Mazumdar-Shaw said.
Ruby Khatun joined Medical Dialogue as Reporter in 2016. She covers all the business news in different categories. She also covers all the updates in Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a post graduate from Jamia Hamdard. She can be contacted at email@example.com Contact no. 011-43720751